Johnson & Johnson Statement on CDC Advisory Committee Meeting on Company COVID-19 Vaccine
NEW BRUNSWICK, N.J., April 14, 2021 – The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) convened today to consider reports of an extremely rare disorder involving blood clots in combination with low platelets observed in a small number of individuals following vaccination with the Johnson & Johnson COVID-19 vaccine. “The safety and well-being of the people who use our products is our number one priority, and we strongly support awareness of the signs and symptoms of this extremely rare event to ensure the correct diagnosis, appropriate treatment an...
Source: Johnson and Johnson - April 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

AstraZeneca vaccine: Seven reported side effects that 'prompt medical advice' - PHE
BLOOD clots have been designated a very rare side effect of the AstraZeneca vaccine but overall benefits of getting the vaccine far outweigh the risk, the European Medicines Agency has concluded. According to Public Health England , there are seven symptoms associated with the jab that should "prompt medical advice". (Source: Daily Express - Health)
Source: Daily Express - Health - April 12, 2021 Category: Consumer Health News Source Type: news

AstraZeneca vaccine: 'Pin-prick rash' and six other side effects that require medical help
BLOOD clots have been designated a very rare side effect of the AstraZeneca vaccine but overall benefits of getting the vaccine far outweigh the risk, the European Medicines Agency has concluded. According to Public Health England , there are seven symptoms associated with the jab that should "prompt medical advice". (Source: Daily Express - Health)
Source: Daily Express - Health - April 12, 2021 Category: Consumer Health News Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Media News - April 12, 2021 Category: Pharmaceuticals Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Investor Update - April 12, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca Vaccine and Blood Clots: What Is Known So Far
In rare cases, an immune reaction has led to antibodies that caused a serious clotting disorder. But public health experts maintain the vaccine ’s benefits far outweigh the risks for most people. (Source: NYT Health)
Source: NYT Health - April 10, 2021 Category: Consumer Health News Authors: Benjamin Mueller and Denise Grady Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Blood Clots European Medicines Agency Research your-feed-healthcare Source Type: news

Blood Clots Linked to AZ Vaccine Stem From Rare Antibody Reaction
New studies from Germany and Norway examined cases involving mostly younger people who developed serious and sometimes fatal blood disorders. (Source: NYT Health)
Source: NYT Health - April 9, 2021 Category: Consumer Health News Authors: Denise Grady Tags: Vaccination and Immunization Antibodies Regulation and Deregulation of Industry AstraZeneca PLC European Medicines Agency New England Journal of Medicine your-feed-healthcare Source Type: news

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines? New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?
The European Medicines Agency has started a review of safety signals in regard to capillary leak syndrome with the AstraZeneca vaccine and unusual blood clots with Johnson& Johnson's Janssen vaccine.News Alerts (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 9, 2021 Category: Primary Care Tags: Neurology & Neurosurgery News Alert Source Type: news

Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot. In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news

Blood Clots a Very Rare Side Effect of AstraZeneca Vaccine: EMA
The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks. (Source: The Scientist)
Source: The Scientist - April 8, 2021 Category: Science Tags: News & Opinion Source Type: news

European Regulators Find Possible Link Between AstraZeneca COVID-19 Vaccine and Rare Clotting Disorder
(LONDON) — The European Union’s drug agency said Wednesday that it found a “possible link” between the AstraZeneca coronavirus vaccine and a rare clotting disorder but recommended that vaccinations continue in adults, saying the benefits of the shot still outweigh risks. The European Medicines Agency described the clots as “very rare” side effects. It said most of the cases reported have occurred in women under 60 within two weeks of vaccination — but based on the currently available evidence, it was not able to identify specific risk factors. Experts reviewed several dozen cases t...
Source: TIME: Health - April 7, 2021 Category: Consumer Health News Authors: MARIA CHENG/AP Tags: Uncategorized COVID-19 Source Type: news

AstraZeneca Covid-19 Vaccine Possibly Linked To Rare Blood Clots, European Medicines Agency Says
The organization recommends rare blood clotting be listed as a very rare side effect of the vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 7, 2021 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news Editors' Pick editors-pick Coronavirus Source Type: news

Official: EU agency to confirm AstraZeneca blood clot link
A top official at the European Medicines Agency says there's a causal link between the AstraZeneca coronavirus vaccine and rare cases of blood clots, but he says the benefits of getting the vaccine still outweigh the risks (Source: ABC News: Health)
Source: ABC News: Health - April 6, 2021 Category: Consumer Health News Tags: Health Source Type: news

EU agency to confirm AstraZeneca COVID-19 vaccine blood clot link, official says
A top official at the European Medicines Agency says there is a causal link between AstraZeneca's coronavirus vaccine and rare blood... (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2021 Category: Consumer Health News Source Type: news

European Medicines Agency's top official links AstraZeneca vaccine and thrombosis
After several countries suspended the use of the jab -- including Italy -- the EMA declared that the benefits outweigh the risks and it should remain in use. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 6, 2021 Category: Pharmaceuticals Source Type: news

U.K. Regulator Recommends Continued Use Of AstraZeneca Vaccine Despite 7 Deaths Linked To Blood Clots
The European Medicines Agency has said that a link between blood clots and the vaccine is "not proven, but is possible." (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 3, 2021 Category: Pharmaceuticals Authors: Tommy Beer, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Coronavirus SportsMoney Source Type: news

EU says 'no evidence' to restrict use of AstraZeneca vaccine
The European Medicines Agency says there is “no evidence” that would support restricting the use of AstraZeneca’s coronavirus vaccine in any population despite reports of rare blood clots associated with the shot (Source: ABC News: Health)
Source: ABC News: Health - March 31, 2021 Category: Consumer Health News Tags: Health Source Type: news

European suspension of AstraZeneca vaccine WILL cause Covid deaths, experts warn
The European Medicines Agency (EMA) said the benefits of protecting against Covid far outweighed the risk of the extremely rare brain clots. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2021 Category: Consumer Health News Source Type: news

Pfizer-BioNTech ’s COVID-19 Vaccine Works for Teens, According to a New Study
Pfizer-BioNTech says their COVID-19 vaccine is 100% efficacious in protecting adolescents aged 12 to 15 years from COVID-19 disease. On March 31, the companies released a statement summarizing the results of their study of the safety and efficacy of their vaccine, which is already authorized in the U.S. and elsewhere for use in adults 16 years or older, in this younger age group. The results have been highly anticipated as state and local leaders—not to mention parents—are to keen send teens back to in-person school; this study suggests a path towards a return to pre-pandemic learning conditions, in which stude...
Source: TIME: Health - March 31, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

EMA issues advice on use of regdanvimab for treating COVID-19
Following a review of the data, the European Medicines Agency has concluded that regdanvimab is appropriate for the treatment of confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 30, 2021 Category: Consumer Health News Source Type: news

Norwegian doctor says AstraZeneca jab is, in fact, causing deadly blood clots
(Natural News) As the world awaited a decision by the European Medicines Agency (EMA) as to the fate of the AstraZeneca and University of Oxford vaccine injection for the Wuhan coronavirus (Covid-19), a doctor in Norway had already determined it to be unsafe. Pal Andre Holme, a chief physician and professor, told Norwegian newspapers just... (Source: NaturalNews.com)
Source: NaturalNews.com - March 29, 2021 Category: Consumer Health News Source Type: news

European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Enfortumab vedotin to be reviewed under accelerated assessment for the treatment of locally advanced or metastatic urothelial cancer TOKYO and BOTHELL, Wash., March 26, 2021 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, ... Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, enfortumab vedotin, urothelial cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2021 Category: Pharmaceuticals Source Type: news

BioNTech provides update on vaccine production status at Marburg manufacturing site
BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg site over the course of this week. (Source: World Pharma News)
Source: World Pharma News - March 26, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

EU regulators probing whether the Pill was behind blood clots linked to AstraZeneca's Covid vaccine
The European Medicines Agency (EMA) is investigating if these were behind the blood clots, its chief executive Emer Cooke (left) said. Britain's regulators are also investigating. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2021 Category: Consumer Health News Source Type: news

Vaccine Safety Board Chides AstraZeneca for Using ‘Outdated’ Data in Press Release About its COVID-19 Shot
In an unusual move, on March 23 the U.S. National Institute of Allergy and Infectious Diseases (NIAID) issued a strongly worded statement asking AstraZeneca to “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.” On March 22, AstraZeneca released the results of its long-awaited U.S. trial of its COVID-19 vaccine, developed with scientists from Oxford University’s Jenner Institute. The data showed that the two-dose vaccine was 79% efficacious in protecting people from symptoms of COVID-19, and 100% efficacious in protecting against severe disease. That data, however, ...
Source: TIME: Health - March 23, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

AstraZeneca vaccine side effects: 'Arm coldness' and other reasons to seek medical help
ASTRAZENECA'S coronavirus vaccine has faced intense scrutiny over the last week as fears of blood clots mounted. The European Medicines Agency found no evidence that the vaccine causes blood clots, but it has outlined reasons to seek medical assistance following your jab. (Source: Daily Express - Health)
Source: Daily Express - Health - March 23, 2021 Category: Consumer Health News Source Type: news

AstraZeneca vaccine side effects: 'Reddish' spots and other reasons to seek medical help
ASTRAZENECA'S coronavirus vaccine has faced intense scrutiny over the last week as fears of blood clots mounted. The European Medicines Agency found no evidence that the vaccine causes blood clots, but it has outlined reasons to seek medical assistance following your jab. (Source: Daily Express - Health)
Source: Daily Express - Health - March 23, 2021 Category: Consumer Health News Source Type: news

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
             Basel, 23 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients (n=4,567; REGN-COV 2067). The phase III outcomes trial in high-risk non-hospitalised patients with COVID-19 met its primary endpoint, showing the investigational antibody cocktail of casirivimab and imdevimab reduced the risk of hospitalisation or death by 70% (1,200 mg intravenously [IV]) and 71% (2,400 mg IV) compared to placebo. Casirivimab and imd...
Source: Roche Investor Update - March 23, 2021 Category: Pharmaceuticals Source Type: news

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
             Basel, 23 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients (n=4,567; REGN-COV 2067). The phase III outcomes trial in high-risk non-hospitalised patients with COVID-19 met its primary endpoint, showing the investigational antibody cocktail of casirivimab and imdevimab reduced the risk of hospitalisation or death by 70% (1,200 mg intravenously [IV]) and 71% (2,400 mg IV) compared to placebo. Casirivimab and imd...
Source: Roche Media News - March 23, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca ’s U.S. Study May Answer Some of the Lingering Questions About Its Vaccine
This study puts to bed any doubts that this isn’t a highly effective vaccine against COVID-19 disease and COVID-19 symptoms,” says Mene Pangalos, executive vice president for biopharmaceuticals research and development at AstraZeneca. AstraZeneca’s vaccine is based on technology developed by scientists at Oxford University’s Jenner Institute, and involves using a chimpanzee adenovirus modified so it cannot cause the cold infection it normally does. The chimp virus acts as a vehicle to deliver genes into the body, where it encodes the SARS-CoV-2 spike protein; cells then process the protein so the im...
Source: TIME: Health - March 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Why Europe ’s AstraZeneca Vaccine Woes Are a Problem for the World
Plenty of drama in Europe this past week as the AstraZeneca vaccine—a crucial component of the continent’s vaccination plans—was paused by more than a dozen European countries after a few reports emerged of blood clots in people after receiving the vaccine. Europe’s FDA equivalent, the European Medicines Agency (EMA), says that it is still “safe and effective” and “its benefits… outweigh the possible risks,” even if they are unable to completely rule out a link between the vaccine and a very rare clotting disorder. But it’s the vaccine politics that are the probl...
Source: TIME: Health - March 22, 2021 Category: Consumer Health News Authors: Ian Bremmer Tags: Uncategorized COVID-19 Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca Covid vaccine 79% effective with no increased blood clot risk – US trial
Study of 21,583 people included specific review of risks of cerebral venous sinus thrombosisCoronavirus – latest updatesSee all our coronavirus coverageAstraZeneca and Oxford University ’s Covid-19 vaccine was 79% effective in a large US trial into preventing symptomatic illness, and was 100% effective against severe or critical disease and hospitalisation, the drugmaker said on Monday.The fresh data comes after many countries resume use of the vaccine after the European Medicines Agency (EMA) and the World Health Organization (WHO) said the benefitsoutweighed the risks following investigations into reports of ...
Source: Guardian Unlimited Science - March 22, 2021 Category: Science Authors: Reuters Tags: Vaccines and immunisation Coronavirus US news World news Infectious diseases Medical research Health Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Malawi: EU Regulator Gives Malawi All-Clear Astrazeneca Jab
[Nyasa Times] Several days after many nations paushed the use of Oxford/AstraZeneca's vaccine - which Malawi is also administering - over blood clot concerns, European Medicines Agency has concluded that the vaccine is "safe and effective "in preventing Covid-19 and its benefits far outweigh the risks. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 19, 2021 Category: African Health Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

European Medicines Agency Finds No Link Between AstraZeneca Vaccine And Blood Clots
The agency's conclusion comes as the Biden administration announced it would send AstraZeneca vaccines to Canada and Mexico. (Source: NPR Health and Science)
Source: NPR Health and Science - March 19, 2021 Category: Consumer Health News Authors: Jason Beaubien Source Type: news

AZ Vaccine Safe Overall but Questions Remain over Unusual Clots AZ Vaccine Safe Overall but Questions Remain over Unusual Clots
The European Medicines Agency says the Oxford/AstraZeneca vaccine is safe but further monitoring is needed based on a small number of cases of rare but serious clotting disorders, in some cases fatal.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 19, 2021 Category: Internal Medicine Tags: Cardiology News Source Type: news

AstraZeneca Vaccine Safe and Effective, European Medicines Agency Says
THURSDAY, March 18, 2021 -- The AstraZeneca COVID-19 vaccine is safe and effective, the European Union drug regulator said Thursday. Officials hope the announcement from the European Medicines Agency will ease concerns about possible rare side... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 18, 2021 Category: Pharmaceuticals Source Type: news

Where is the AstraZeneca vaccine made in the UK?
THE OXFORD/ ASTRAZENECA vaccine has been cleared as safe according to the European Medicines Agency following concerns about blood clots after receiving the jab. But where is the AstraZeneca vaccine made in the UK? (Source: Daily Express - Health)
Source: Daily Express - Health - March 18, 2021 Category: Consumer Health News Source Type: news

European Medicines Agency Finds AstraZeneca Vaccine Safe And Effective
(Source: NPR Health and Science)
Source: NPR Health and Science - March 18, 2021 Category: Consumer Health News Authors: Laurel Wamsley Source Type: news

We welcome verdict on Oxford-AstraZeneca vaccine
Following the review of the Oxford-AstraZeneca Covid-19 vaccine by the European Medicines Agency (EMA), which concluded it is"safe and effective," RPS Chief Scientist Professor Gino Martini (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 18, 2021 Category: Drugs & Pharmacology Source Type: news

AstraZeneca Vaccine Is Safe, Europe's Drug Regulator Says
Millions of people have received the shots without safety problems, and the European Medicines Agency found no evidence of any causal... (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2021 Category: Consumer Health News Source Type: news

European regulator greenlights AstraZeneca coronavirus vaccine after reports of blood clots
The European Medicines Agency has ruled that the AstraZeneca coronavirus vaccine is safe, despite some concerns over possible side effects. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2021 Category: Consumer Health News Source Type: news

UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
Today the Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks. Earlier today, the MHRA announced their review of the small number of thromboembolic events in over 11 million people who received COVID-19 Vaccine AstraZeneca in the UK. (Source: World Pharma News)
Source: World Pharma News - March 18, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

EMA Warns of Eylea Injection Risk EMA Warns of Eylea Injection Risk
The European Medicines Agency is warning that syringes prefilled with aflibercept for intravitreal injection can cause elevated intraocular pressure if not handled properly.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 18, 2021 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Experts now claim they will explore the potential link of AstraZeneca jab to blood clots and other serious conditions
(Natural News) On Tuesday, March 16, European Medicines Agency (EMA) Executive Director Emer Cooke said that experts were assessing the possibility that the AstraZeneca-Oxford coronavirus (COVID-19) jab contributed to the blood clots and other possible adverse reactions suffered by certain patients who received the vaccine. “The experts will meet again on Thursday to come to... (Source: NaturalNews.com)
Source: NaturalNews.com - March 18, 2021 Category: Consumer Health News Source Type: news

Germany joins European cohort in halting AstraZeneca coronavirus vaccinations
(Natural News) Following a spate of deadly blood clots all across Europe, Germany has decided to join more than a dozen other European nations in halting all further administration of Wuhan coronavirus (Covid-19) vaccines from AstraZeneca. Though the European Medicines Agency (EMA) still insists the jabs are “safe,” Germany, Iceland, and several other EU nations... (Source: NaturalNews.com)
Source: NaturalNews.com - March 17, 2021 Category: Consumer Health News Source Type: news

EMA: Benefit of AstraZeneca's COVID Vaccine Outweighs Risk, for Now EMA: Benefit of AstraZeneca's COVID Vaccine Outweighs Risk, for Now
As several European Union countries have stopped using AstraZeneca ’'s COVID vaccine because of thromboembolic-event reports, the European Medicines Agency promises to deliver a full assessment on March 18.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 16, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Physicians to EU regulators: Address safety concerns or stop rollout of coronavirus vaccine
(Natural News) A group known as the “Doctors for Covid Ethics” called on the European Medicines Agency (EMA) to answer urgent safety questions about the COVID-19 vaccines that are authorized for use among European Union (EU) countries. Should the EMA fail to address these concerns, the group implores the agency to withdraw authorization for the vaccines. As of March 13, the... (Source: NaturalNews.com)
Source: NaturalNews.com - March 16, 2021 Category: Consumer Health News Source Type: news